FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the USBusiness Wire • 09/09/20
Innoviva (INVA) Dips More Than Broader Markets: What You Should KnowZacks Investment Research • 05/28/20
Innoviva (INVA) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research • 01/08/20